Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial.

Abstract

CONTEXT:

Chronic obstructive pulmonary disease (COPD) is recognized as a major healthcare problem in the United States and around the world.

OBJECTIVE:

This survey regarding initial experience in patients with COPD collected feedback about newly initiated therapy with fluticasone propionate/salmeterol (FSC; ADVAIR DISKUS).

DESIGN:

Three telephone surveys were conducted; Survey 1 prior to initiating therapy with FSC 250/50, and Surveys 2 and 3 at 2 weeks and 30 days after initiating therapy with FSC 250/50, respectively.

SETTING:

One thousand primary care physicians recruited outpatients into the trial.

PATIENTS:

Patients were either newly diagnosed with COPD associated with chronic bronchitis or were still experiencing breathing difficulties on an anticholinergic medication.

INTERVENTIONS:

Patients initiated FSC 250/50 and received a 1-month supply of FSC 250/50 with an albuterol inhaler for rescue use.

MAIN OUTCOME MEASURES:

Outcome measures were patient perceptions of satisfaction, compliance, and convenience and changes in breathing on 1 (negative) to 9 (positive) point scales.

RESULTS:

Five hundred sixteen patients completed all 3 surveys. The mean age was 61 years, 63% were female, and 62% had been diagnosed with COPD associated with chronic bronchitis for 3 years or less (Table 1).

CONCLUSION:

Patients reported high satisfaction, compliance, and convenience with FSC 250/50 within 2 weeks of initiating therapy, all maintained over the trial period. Additionally, patients had positive changes in breathing, including improvements in the ability to breathe upon awakening in the morning.

• Authors: Stuart Stoloff, Steven Samuels, Donna Kerney, Christy P Brown
• Journal: MedGenMed : Medscape general medicine (MedGenMed) Vol. 8 Issue 1 Pg. 86 (Mar 29 2006) ISSN: 1531-0132 [Electronic] United States
• PMID: 16915216 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Androstadienes
• Drug Combinations
• Fluticasone-Salmeterol Drug Combination
• Albuterol

Topics

• Administration, Inhalation
• Albuterol (administration & dosage, analogs & derivatives)
• Androstadienes (administration & dosage)
• Bronchitis, Chronic (complications)
• Drug Combinations
• Female
• Fluticasone-Salmeterol Drug Combination
• Humans
• Male
• Middle Aged
• Patient Satisfaction
• Pulmonary Disease, Chronic Obstructive (complications, drug therapy)